Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the ...
PLYMOUTH MEETING, Pennsylvania, July 8, 2019 /PRNewswire-AsiaNet/ -- --Biotech company will report interim data later this yearInovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulva...
Authors: LATEST ASIANET NEWS RELEASES